Table 1.
Characteristics of APL patients and controls.
| Control (n = 30) | APL (n = 32) | |
|---|---|---|
| Age, y | 41 ± 3 | 49.5 ± 15.39 |
| Gender, male/female | 16/14 | 21/11 |
| BMI, kg/m2 | 26.4 ± 0.21 | 24.4 ± 0.2 |
| Diagnosis | ||
| M3/bcr1, n% | – | 10 (31.25) |
| M3/bcr2, n% | – | 11 (34.38) |
| M3/bcr3, n% | – | 11 (34.38) |
| WBC, × 109 | 6.3 ± 0.11 | 22.3 ± 8.1* |
| Hb, g/L | 132.5 ± 0.85 | 89.8 ± 5.6 * |
| PLTs, × 109 | 230 ± 3.7 | 42.2 ± 8.1 * |
| Blasts, BM% | – | 42.4 ± 4.86 |
| PT, s | 12.73 ± 0.1 | 13.89 ± 0.4 * |
| APTT, s | 28.2 ± 0.5 | 29.8 ± 1 |
| Fibrinogen, g/L | 2.9 ± 0.1 | 1.9 ± 0.2 * |
| D-dimer, mg/mL | 0.25 ± 0.01 | 5.7 ± 0.9 * |
The major clinical and laboratory characteristics of 30 healthy controls and 32 newly diagnosed APL patients are shown. Data are presented as numbers (percentages) or the median ± SD or median values (25th and 75th percentiles). BMI, body mass index (r.v. 18.5–25 kg/m2); Bcr, breakpoint cluster region (bcr1 = intron 6, bcr2= exon 6, bcr3 = intron 3); WBC, white blood cell; PLT, platelet; Hb, haemoglobin; PT, prothrombin time (r.v. 10–15 s); Blasts, promyelocytes + blasts; BM, bone marrow; APTT, activated partial thromboplastin time (r.v. 20–40 s).
⁎
P < 0.05 vs. healthy controls.